

09-13-04

DFW

Certificate of Mailing (37 C.F.R. §1.10):

I hereby certify that this correspondence is being deposited with the United States Postal Service as Express Mail (EV 386659475 US) in an envelope addressed to: Commissioner for Patents, PO Box 1450, Alexandria, VA 22313-1450, on this 9th day of September 2004.

s/ Pamela Hollander  
Pamela Hollander



**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re the Application of: **James FREDDO, et al.**

Serial No.: **10/816,242**

Confirmation No.: **9207**

Filed: **April 1, 2004**

For: **DOSAGE FORMS AND METHODS OF TREATMENT USING VEGFR INHIBITORS**

Group Art Unit: **1614**

Examiner: **Not Yet Assigned.**

Honorable Commissioner For Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**TRANSMITTAL OF**

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**

**UNDER 37 C.F.R. § 1.97(b) or 1.97(c)**

**37 CFR § 1.97(b)**

- ☒ The Information Disclosure Statement submitted herewith is being filed within three months of the filing date of a national application other than a continued prosecution application under § 1.53(d); within three months of the date of entry of the national stage as set forth in § 1.491 in an international application; before the mailing of a first Office Action on the merits; or before the mailing of a first Office Action after the filing of a request for continued examination under § 1.114.

**37 CFR § 1.97(c)**

- ☐ The Information Disclosure Statement submitted herewith is being filed after three months of the filing date of a national application other than a continued prosecution application under § 1.53(d); after three months of the date of entry of the national stage as set forth in § 1.491 in an international application; after the mailing of a first Office Action on the merits; or after the mailing of a first Office Action after the filing of a request for continued examination under § 1.114, but before the mailing date of (1) a Final Action under § 1.113; (2) a Notice of Allowance under § 1.311; or (3) an action that otherwise closes prosecution in the application. The Commissioner is hereby authorized to charge the fee as set forth in § 1.17(p) to Deposit Account Number 500329.

- ☐ Applicant requests that the Examiner consider the following copending applications:


| Application Serial No. | Filing Date |
|------------------------|-------------|
|                        |             |
|                        |             |
|                        |             |

- ☐ Copies of these copending applications are enclosed.
- ☒ Applicant hereby requests consideration of the Information Disclosure Statement, USPTO form 1449, submitted herewith. Copies of the cited references, except as noted below, are enclosed.
- ☐ This application is a continuation, divisional or continuation-in-part of Serial No. . Copies of the cited references, if not enclosed, are available in the file of the parent application or parents thereof.
- ☒ This application was filed after June 30, 2003, or entered U.S. national stage under 35 U.S.C. § 371, after June 30, 2003. Copies of U.S. Patents and U.S. Patent Application Publications are not enclosed. (1276 OG 55).
- ☐ Applicant hereby requests consideration of the enclosed International Search Report, which was received in a related international patent application.

The Commissioner is hereby authorized to charge any fee deficiency, including any fee required under 37 C.F.R. § 1.17(p), or credit any overpayment, to Deposit Account Number 500329. A duplicate copy of this form is enclosed.

Respectfully submitted,

Date: September 9, 2004

  
Matthew J. Pugmire  
Attorney For Applicant  
Registration No. 54,723

Agouron Pharmaceuticals, Inc./A Pfizer Company  
Patent Department  
10777 Science Center Drive  
San Diego, California 92121  
Phone: (858) 638-6349  
Fax: (858) 678-8233

PC25581A US  
Supplemental Information Disclosure Statement  
For Appln. No. 10/816,242



Certificate of Mailing (37 C.F.R. §1.10):  
I hereby certify that this correspondence is being deposited with the United States Postal Service as Express Mail (EV 386659475 US) in an envelope addressed to: Commissioner for Patents, PO Box 1450, Alexandria, VA 22313-1450, on this 9th day of September 2004.

s/ Pamela Hollander  
Pamela Hollander

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of: **James FREDDO, et al.**

Serial No.: **10/816,242**

Confirmation No.: **9207**

Filed: **April 1, 2004**

For: **DOSAGE FORMS AND METHODS OF TREATMENT USING VEGFR INHIBITORS**

Group Art Unit: **1614**

Examiner: **Not Yet Assigned**

Honorable Commissioner For Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**TRANSMITTAL LETTER**

Transmitted herewith are the following documents:

Return Receipt Postcard  
Transmittal of Supplemental Information Disclosure Statement  
PTO.SB/08A Form 1449  
Copies of Cited References  
Fee Due

**1 postcard;  
2 pages;  
1 page;  
6 references; and  
Deposit Account.**

Respectfully submitted,

Date: **September 9, 2004**

Matthew J. Pugmire  
Matthew J. Pugmire  
Attorney For Applicant  
Registration No. 54,723

Agouron Pharmaceuticals, Inc./A Pfizer Company  
Patent Department  
10777 Science Center Drive  
San Diego, California 92121  
Phone: (858) 638-6349  
Fax: (858) 678-8233

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control Number.

Substitute for form 1449/PTO

**Supplemental  
INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
(Use as many sheets as necessary)

**Complete if Known**

|                        |                 |
|------------------------|-----------------|
| Application Number     | 10/816,242      |
| Filing Date            | April 1, 2004   |
| First Named Inventor   | James FREDDO    |
| Art Unit               | 1614            |
| Examiner Name          | To be Assigned. |
| Attorney Docket Number | PC25881A US     |

**NON PATENT LITERATURE DOCUMENTS**

| Examiner Initials | Cite No. <sup>1</sup> | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.   | T <sup>2</sup> |
|-------------------|-----------------------|---|----------------|
|                   | AA                    | HU-LOWE, D., et al., "Pharmacological Activities of AG013736, a Small Molecule Inhibitor of VEGF/PDGR Receptor Tyrosine Kinases," <i>Proceedings of the American Association for Cancer Research Annual Meeting</i> , March 2002, p. 1082, Vol. 43  |                |
|                   | AB                    | LAIRD, D.A., et al., "Small Molecule Tyrosine Kinase Inhibitors: Clinical Development of Anticancer Agents," <i>Expert Opinion on Investigational Drugs</i> , January 2003, pp. 51-64, 01, Vol. 12, No. 1   |                |
|                   | AC                    | MARME, D., "The Impact of Anti-angiogenic Agents on Cancer Therapy," <i>J. Cancer Res. Clin. Oncol.</i> , November 2003, pp. 607 – 620, Vol. 129, No. 11.   |                |
|                   | AD                    | SAKI, P., et al. "AG-013736, a Potent VEGF/PDGF Receptor Tyrosine Kinase Inhibitor, is Active Against Lymphoma Growth and Chemotherapy-induced Vasculogenesis," <i>Blood</i> , November 16, 2003, p. 649a, Vol. 102, No. 11.  |                |
|                   | AE                    | WICKMAN, G., et al., "Further Characterization of the Potent VEGF/PDGF Receptor Tyrosine Kinase Inhibitor AG-013736 in Preclinical Tumor Models for its Antiangiogenesis and Antitumor Activity," <i>Proceedings of the American Association for Cancer Research Annual Meeting</i> , July 2003, pp. 752-753, Vol. 44., 2 <sup>nd</sup> ed. |                |
|                   | AF                    | WILMES, L.J., et al., "AG -013736, a Novel VEGFR TK Inhibitor, Suppresses Tumor Growth and Vascular Permeability in Human BT474 Breast Cancer Xenografts in Nude Mice," <i>Proceedings of the American Association for Cancer Research Annual Meeting</i> , July 2003, p. 751, Vol. 44. 2 <sup>nd</sup> ed.                                 |                |

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public, which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. Send to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.